In summary, our case report presented a lung adenocarcinoma patient who developed a novel METex14 skipping mutation (c.2888-23_2888-8del) after acquiring resistance to EGFR-TKIs treatment and exhibited clinical benefits from savolitinib therapy. Here, EGFR is linked to lung adenocarcinoma.